Treatment of Psoriasis in HIV Infection on Highly Active Antiretroviral Therapy
Clinical Scenario
HIV + HAART
Managing psoriasis in a patient with HIV infection who is already on highly active antiretroviral therapy (HAART) requires careful consideration of immunological status. Standard immunosuppressive approaches used in psoriasis may not be appropriate in this setting.
Why This Scenario Is Distinct
Because acitretin is not immunosuppressive, it is often used in patients with psoriasis on highly active antiretroviral therapy treatment of HIV. The choice of agent in this population is specifically shaped by the need to avoid further compromise of immune function.
Treatment Approach (Partial Overview)
The protocol for this scenario centres on a non-immunosuppressive oral retinoid — a class of agent selected precisely because it does not suppress immune activity, making it suitable for patients on HAART.
Full regimen details, dosing, and clinical decision algorithm available in the complete protocol below.
Treatment Goals
Clearance of psoriatic skin lesions with full treatment response by 3 to 6 months.
References
- Because acitretin is not immunosuppressive, it is often used in patients with psoriasis on highly active antiretroviral therapy treatment of HIV.
- Acitretin is administered for psoriasis in doses ranging from 10 to 50 mg daily.
- Acitretin is a relatively slow-acting medication that can take 3 to 6 months for full treatment response.
DOI: 10.1016/j.jaad.2020.02.044
View source ↗